Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582283 · ClinicalTrials.gov registry record · Phase 1
NM404 as an Imaging Agent in Patients With NSCLC
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00582283 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 21 participants.
The verdict
NCT00582283, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study seeks to determine imaging characteristics of radiolabelled 131-I-NM404 in ten patients with cancer, including calculations of PKs, radiation dosimetry, biodistribution, and optimal imaging times (part 1 - complete). In addition, specific tumor accumulation and metabolic fate of 131-I-NM404 will be determined in NSCLC tumors collected in 5 patients (part 2 - complete). Lastly, the study will collect preliminary data on imaging NSCLC tumors in up to 12 patients with evaluable disease (part 3 - ongoing).
Interventions
- DRUG I124-NM404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-01-14 |
| Est. Completion | 2014-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582283
The ClinicalTrials.gov registry entry for NCT00582283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which I124-NM404 is the first listed.
NCT00582283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582283 about?
NCT00582283 is a clinical study titled "NM404 as an Imaging Agent in Patients With NSCLC". This study seeks to determine imaging characteristics of radiolabelled 131-I-NM404 in ten patients with cancer, including calculations of PKs, radiation dosimetry, biodistribution, and optimal imaging times (part 1 - complete). In addition, specific tumor accumulation and metabolic fate of 131-I-NM...
What is the current status of trial NCT00582283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2004-01-14. Estimated completion is 2014-08-01.
What interventions are being tested in trial NCT00582283?
The interventions under investigation include: I124-NM404 (DRUG).
Who is sponsoring clinical trial NCT00582283?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.